[1]齐璐瑶,邢基祥,范吉林,等.基于网络药理学探讨参蛭通心胶囊核心药对人参-水蛭治疗扩张型心肌病的作用机制[J].西部中医药,2024,37(03):44-51.[doi:10.12174/j.issn.2096-9600.2024.03.09]
　QI Luyao,XING Jixiang,FAN Jilin,et al.Study on the Mechanism of Core Drug Pair Ginseng-Leech of Shenzhi Tongxin Capsule in the Treatment of Dilated Cardiomyopathy Based on Network Pharmacology[J].Western Journal of Traditional Chinese Medicine,2024,37(03):44-51.[doi:10.12174/j.issn.2096-9600.2024.03.09]
点击复制

基于网络药理学探讨参蛭通心胶囊核心药对人参-水蛭治疗扩张型心肌病的作用机制
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
37
期数:
2024年03期
页码:
44-51
栏目:
二次研究
出版日期:
2024-03-15

文章信息/Info

Title:
Study on the Mechanism of Core Drug Pair Ginseng-Leech of Shenzhi Tongxin Capsule in the Treatment of Dilated Cardiomyopathy Based on Network Pharmacology
作者:
齐璐瑶1, 邢基祥1, 范吉林1, 侯信铮1, 陈昭1, 张世亮2
1.山东中医药大学，山东 济南 250014
2.山东中医药大学附属医院，山东 济南 250014
Author(s):
QI Luyao1, XING Jixiang1, FAN Jilin1, HOU Xinzheng1, CHEN Zhao1, ZHANG Shiliang2
1.Shandong University of Traditional Chinese Medicine, Jinan 250014, China
2.Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250014, China
关键词:
扩张型心肌病; 网络药理学; 参蛭通心胶囊; 人参-水蛭; 作用机制
Keywords:
dilated cardiomyopathy; network pharmacology; Capsule; ginseng and leech; mechanism
分类号:
R256.21
DOI:
10.12174/j.issn.2096-9600.2024.03.09
文献标志码:
A
摘要:
目的基于网络药理学方法探究参蛭通心胶囊核心药对人参-水蛭治疗扩张型心肌病（dilated cardiomyopathy，DCM）的作用机制。 方法通过中药系统药理学数据库与分析平台（traditional Chinese medicine systems pharmacology database and analysis platform，TCMSP）、BATMAN-TCM数据库获取人参-水蛭药对的活性成分及潜在靶点并导入UniProt数据库对所得基因进行标准化处理；运用人类基因数据库（the human gene database，GeneCards）获取DCM已知靶点；通过绘制韦恩图得到药物与疾病的交集靶点，将药物活性成分及药物-疾病共同靶点等数据导入Cytoscape 3.7.2软件，构建药物-成分-疾病-靶点网络；运用STRING数据库构建蛋白-蛋白互作网络（protein-protein interactions，PPI）并筛选出核心靶点；将核心靶基因导入基因功能注释数据库（the database for annotation visualization and integrated discovery，DAVID）平台对所得交集靶点进行基因本体（gene ontology，GO）和京都基因与基因组百科全书（kyoto encyclopedia of genes and genomes，KEGG）通路富集分析，同时利用OmicShare进行数据的可视化分析。 结果经筛选共获得人参-水蛭药对有效成分35个，药物-疾病交集靶点184个，涉及的核心靶点主要有胰岛素、白蛋白、肿瘤坏死因子、内皮一氧化氮合成酶、过氧化物酶体增殖物激活受体、白细胞介素1β等。人参-水蛭的有效成分通过对细胞膜、细胞外间隙、电压门控钙通道复合体等部位的作用、一氧化氮生物合成过程的正调控、细胞间信号传递、对凋亡过程的负调控等过程和CAMP信号通路等在内的多个信号通路协同作用治疗DCM。 结论参蛭通心胶囊的核心药对人参-水蛭可以通过参与调控多成分、多靶点、多通路治疗DCM。
Abstract:
ObjectiveTo explore the mechanism of the core drug pair ginseng and leech in Shenzhi Tongxin Capsule in the treatment of dilated cardiomyopathy (DCM) based on network pharmacology. MethodsThe active ingredients and potential targets of drug pair ginseng and leech were gained through TCMSP and BATMAN-TCM databases, to perform the standardized processing after imported into the Uniprot database. The known targets of DCM were obtained using the GeneCards database. The intersection targets of drugs and diseases were obtained by drawing a Venn diagram. The data on active ingredients of the drugs and drug-disease common targets was introduced into Cytoscape 3.7.2 software to construct a drug-component-disease-target network. Protein-protein interaction (PPI) network was constructed and core targets were screened out using the STRING database. DAVID database platform was used to perform GO function and KEGG pathway enrichment analysis of the obtained intersection targets, at the same time, Omicshare was applied for visualization analysis of the data. ResultsAfter screening, a total of 35 effective ingredients were obtained, corresponding to 184 targets. The core targets involved mainly included insulin (INS), albumin (ALB), tumor necrosis factor (TNF), endothelial nitric oxide synthase (NOS3), peroxisome proliferator activated receptor (PPARG), interleukin-1β, etc. The active ingredients of ginseng-leech could treat DCM through synergistic effects of multiple signaling pathways, including cell membrane, extracellular space, voltage-gated calcium channel complex, positive regulation of nitric oxide biosynthesis process, intercellular signal transduction, negative regulation of apoptosis process, and CAMP signaling pathway. ConclusionThe core drug pair ginseng-leech of Shenzhi Tongxin capsule could treat DCM by participating in the regulation of multiple ingredients, multiple targets and multiple pathways.

相似文献/References:

[1]何文,董耀荣,陈兆善,等.强心方对扩张型临床心衰期心肌病患者心功能及血浆脑钠肽水平的影响[J].西部中医药,2013,26(07):4.
　HE Wen,DONG Yaorong,CHEN Zhaoshan,et al.Effects of QiangXin Prescription on Cardiac Function and Plasma Brain Natriuretic Peptide of Patients with Dilated Cardiomyopathy at the Stage of Heart Failure[J].Western Journal of Traditional Chinese Medicine,2013,26(03):4.
[2]刘新宇,陈星宇,毕鸿昊,等.基于网络药理学和分子对接探讨枸杞子-菟丝子-当归治疗视网膜色素变性的作用机制[J].西部中医药,2025,38(12):79.[doi:10.12174/j.issn.2096-9600.2025.12.16]
　LIU Xinyu,CHEN Xingyu,BI Honghao,et al.Exploring the Mechanism of Action of Gouqizi-Tusizi-Angelica in the Treatment of Retinitis Pigmentosa Based on Network Pharmacology and Molecular Docking[J].Western Journal of Traditional Chinese Medicine,2025,38(03):79.[doi:10.12174/j.issn.2096-9600.2025.12.16]
[3]杨继红,姚帅君,贺文彬,等.基于数据挖掘和分子对接探讨含党参方剂治疗消渴用药规律及分子机制研究[J].西部中医药,2025,38(08):30.[doi:10.12174/j.issn.2096-9600.2025.08.08]
　YANG Jihong,YAO Shuaijun,HE Wenbin,et al.Medication Rules of Dangshen-containing Prescription in the Treatment of Diabetes Mellitus and Study on Molecular Mechanism: Based on Data Mining and Molecular Docking[J].Western Journal of Traditional Chinese Medicine,2025,38(03):30.[doi:10.12174/j.issn.2096-9600.2025.08.08]
[4]赵贺华,杨丽君.基于网络药理学探讨黄芩抗巨细胞病毒感染的作用机制[J].西部中医药,2025,38(08):37.[doi:10.12174/j.issn.2096-9600.2025.08.09]
　ZHAO Hehua,YANG Lijun.Network Pharmacology-based Discussion on the Mechanism of Huangqin in the Treatment of Cytomegalovirus Infection[J].Western Journal of Traditional Chinese Medicine,2025,38(03):37.[doi:10.12174/j.issn.2096-9600.2025.08.09]
[5]顾东彦,王子雯,许孟月,等.基于网络药理学及分子对接探讨参苓白术散治疗特应性皮炎的作用机制[J].西部中医药,2025,38(08):45.[doi:10.12174/j.issn.2096-9600.2025.08.10]
　GU Dongyan,WANG Ziwen,XU Mengyue,et al.Mechanism of Shenling Baizhu Powder in the Treatment of Atopic Dermatitis Based on Network Pharmacology and Molecular Docking[J].Western Journal of Traditional Chinese Medicine,2025,38(03):45.[doi:10.12174/j.issn.2096-9600.2025.08.10]
[6]余林波,周鹍,林谦,等.基于网络药理学和分子对接技术探讨芪参六味方治疗心肌纤维化的作用机制[J].西部中医药,2025,38(08):51.[doi:10.12174/j.issn.2096-9600.2025.08.11]
　YU Linbo,ZHOU Kun,LIN Qian,et al.Based on Network Pharmacology and Molecular Docking: Treatment of Myocardial Fibrosis with Qishen Six-flavor Prescription[J].Western Journal of Traditional Chinese Medicine,2025,38(03):51.[doi:10.12174/j.issn.2096-9600.2025.08.11]
[7]杨竹青,郭敏,徐文倩,等.基于网络药理学和分子对接技术探究绝经后肝纤维化的中药用药规律[J].西部中医药,2025,38(09):46.[doi:10.12174/j.issn.2096-9600.2025.09.10]
　YANG Zhuqing,GUO Min,XU Wenqian,et al.Exploring Medication Rules of Traditional Chinese Medicine in the Treatment of Postmenopausal Liver Fibrosis Based on Network Pharmacology and Molecular Docking[J].Western Journal of Traditional Chinese Medicine,2025,38(03):46.[doi:10.12174/j.issn.2096-9600.2025.09.10]
[8]王莉婷,王成祥,徐广,等.基于网络药理学和分子对接方法探讨红曲茯苓片防治血脂异常的作用机制[J].西部中医药,2025,38(10):72.[doi:10.12174/j.issn.2096-9600.2025.10.13]
　WANG Liting,WANG Chengxiang,XU Guang,et al.Hongqu Fuling Tablets in the Treatment of Dyslipidemia Based on Network Pharmacology and Molecular Docking[J].Western Journal of Traditional Chinese Medicine,2025,38(03):72.[doi:10.12174/j.issn.2096-9600.2025.10.13]
[9]高世龙,杨艳玲,蔡钦钦,等.基于GEO差异表达基因与网络药理学探讨黄芩经铁死亡途径调控2型糖尿病作用机制[J].西部中医药,2025,38(10):81.[doi:10.12174/j.issn.2096-9600.2025.10.14]
　GAO Shilong,YANG Yanling,CAI Qinqin,et al.The Mechanism of Huangqin Regulation in Type 2 Diabetes Mellitus via Ferroptosis Pathway Based on GEO Differentially Expressed Genes and Network Pharmacology[J].Western Journal of Traditional Chinese Medicine,2025,38(03):81.[doi:10.12174/j.issn.2096-9600.2025.10.14]
[10]张津铖,程志强.基于网络药理学和分子对接探讨调脾安肠方治疗结直肠癌的作用机制[J].西部中医药,2025,38(10):90.[doi:10.12174/j.issn.2096-9600.2025.10.15]
　ZHANG Jincheng,CHENG Zhiqiang.Mechanism of Spleen-regulating Intestine-calming Formula in the Treatment of Colorectal Cancer Based on Network Pharmacology and Molecular Docking Technology[J].Western Journal of Traditional Chinese Medicine,2025,38(03):90.[doi:10.12174/j.issn.2096-9600.2025.10.15]

备注/Memo

备注/Memo:
齐璐瑶（1996—），女，在读博士研究生。研究方向：心血管疾病急危重症的中西医结合治疗与康复。国家科技重大专项重大新药创制项目（2017ZX09301003）。
更新日期/Last Update: 2024-03-15